Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tripalma is a topical antimicrobial cream developed by Manuka Biosciences for the treatment of impetigo. It is a botanical-based formulation consisting of a synergistic blend of three essential oils: mānuka oil (*Leptospermum scoparium*), kānuka oil (*Kunzea ericoides*), and palmarosa oil (*Cymbopogon martinii*). The primary active components, particularly the β-triketones found in mānuka oil, exhibit potent antibacterial activity against Gram-positive bacteria, including *Staphylococcus aureus* and *Streptococcus pyogenes*, which are the primary causative agents of impetigo. The formulation is designed as a non-antibiotic alternative to traditional topical treatments like mupirocin or fusidic acid, aiming to reduce the risk of antimicrobial resistance and provide a natural therapeutic option for skin infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tripalma.